Pfizer Stock

Pfizer ROE

The Return on Equity (ROE) of Pfizer (PFIZER.NS) as of Aug 4, 2026 is 18.20 %. In the previous year, Return on Equity (ROE) was 15.33 % — a change of 18.70% (higher).

ROE

18.20 %

YoY

18.70%

Last updated:

In 2026, Pfizer's return on equity (ROE) was 18.20 %, a 18.70% increase from the 15.33 % ROE in the previous year.

Access this data via the Eulerpool API

Pfizer Stock analysis

What does Pfizer do? Pfizer Ltd is a global biopharmaceutical company based in New York City, USA. The company was founded in 1849 by cousins Charles Pfizer and Charles Erhart, and has achieved numerous milestones in the pharmaceutical industry during its 170-year history. Pfizer's business model is based on the research, development, production, and distribution of innovative drugs and vaccines for a variety of diseases. With a diverse portfolio of products, the company's range extends from drugs for cancer, inflammation, and immunology to neurological and cardiology conditions. Pfizer is a global leader in the development of cancer drugs and has achieved groundbreaking research successes in recent years. Key divisions of the company include oncology, pain management, cardiology, and neurology. Pfizer places great emphasis on putting patients and their needs at the center and works closely with medical professionals, patient groups, and authorities to ensure the best possible patient care. Pfizer is a leading provider of vaccines and has achieved significant breakthroughs in the development of COVID-19 vaccines in recent years. In December 2020, the company was one of the first worldwide to bring a vaccine against the coronavirus to market, making a significant contribution to the fight against the pandemic. In addition to drug research and development, Pfizer is also heavily involved in corporate social responsibility. The company is committed to sustainable development and continuously works to reduce its carbon footprint. The Pfizer Foundation also supports numerous nonprofit organizations and projects in the areas of health, education, and environmental protection. Among Pfizer's most well-known products are medications such as Viagra, Lipitor, and Lyrica, as well as the COVID-19 vaccine Comirnaty. Pfizer has offices in over 150 countries and employs over 90,000 people worldwide. Like any global company, Pfizer faces challenges. The company is often criticized for high drug prices and the availability of medications in developing countries. However, Pfizer actively advocates for access to affordable healthcare and delivers drugs and vaccines to all regions of the world. Overall, Pfizer is a company of great importance in the global healthcare industry. Through its research and development of innovative drugs and vaccines, the company contributes to improving the quality of life for millions of people worldwide. Pfizer is one of the most popular companies on Eulerpool.

ROE Details

Decoding Pfizer's Return on Equity (ROE)

Pfizer's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Pfizer's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Pfizer's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Pfizer’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Pfizer stock

Return on Equity (ROE) of Pfizer is 18.20 % in 2026.

Return on Equity (ROE) of Pfizer changed from 15.33 % to 18.20 %, representing a 18.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Pfizer since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Pfizer with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Pfizer

All Key Metrics — Pfizer